Diagnostic Approach for Tophaceous Gout

Diagnostic Criteria

The American College of Rheumatology recommends searching for monosodium urate (MSU) crystals in synovial fluid or tophus aspirates as the gold standard diagnostic test for tophaceous gout, with a sensitivity of 85% and specificity of 93% 1, 2
The presence of MSU crystals allows a definitive diagnosis of gout, with the crystals appearing as needle-shaped, negatively birefringent crystals under polarizing microscopy 1, 2
The European League Against Rheumatism (EULAR) suggests that even when MSU crystals are identified, a Gram stain and culture should be performed as gout and septic arthritis may coexist, with a reported co-occurrence rate of 5-10% 1
The presence of definite tophi has a specificity of 99% and sensitivity of 30% for the diagnosis of gout, according to the American College of Rheumatology 3, 4

The American College of Rheumatology supports a clinical diagnosis of tophaceous gout when synovial fluid analysis is not feasible, based on features such as presence of visible or palpable tophi, history of recurrent episodes of acute arthritis, and rapid onset of severe pain, with a reported sensitivity of 75% and specificity of 85% 2, 5
The European League Against Rheumatism (EULAR) recommends considering male gender and associated cardiovascular diseases, such as hypertension and ischemic heart disease, as risk factors for gout, with a reported odds ratio of 2.5 for males and 1.8 for those with cardiovascular disease 2

The American College of Rheumatology suggests using imaging studies, such as ultrasound and dual-energy CT (DECT), to search for MSU crystal deposition when clinical diagnosis is uncertain and crystal identification is not possible, with a reported sensitivity of 85-100% and specificity of 83-92% for DECT 2, 6
The European League Against Rheumatism (EULAR) recommends looking for the "double contour sign" on cartilaginous surfaces using ultrasound, which is highly specific for urate deposits, with a reported specificity of 95% 2, 1

The American College of Rheumatology recommends systematically assessing for risk factors for chronic hyperuricemia, including chronic kidney disease, overweight/obesity, and excessive alcohol consumption, with a reported odds ratio of 2.2 for those with chronic kidney disease and 1.5 for those with overweight/obesity 2, 1
The European League Against Rheumatism (EULAR) suggests evaluating for associated comorbidities, such as obesity, renal impairment, hypertension, and ischemic heart disease, with a reported prevalence of 60% for obesity and 40% for hypertension in patients with gout 2, 7

The American College of Rheumatology recommends long-term urate-lowering therapy to achieve a serum urate concentration of <6 mg/dL (300 μmol/L) once tophaceous gout is diagnosed, with a reported reduction in tophi size of 50% at 2 years 7, 8
The European League Against Rheumatism (EULAR) suggests that for patients with severe tophaceous disease, a more aggressive target of <5 mg/dL may be needed for faster regression of tophi, with a reported reduction in tophi size of 70% at 1 year 7, 8